- Home
- MOLN vs PROK Comparison
MOLN vs PROK Comparison
Compare MOLN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- PROK
- Stock Information
- Founded
- MOLN 2004
- PROK 2015
- Country
- MOLN Switzerland
- PROK United States
- Employees
- MOLN N/A
- PROK N/A
- Industry
- MOLN
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOLN
- PROK Health Care
- Exchange
- MOLN Nasdaq
- PROK Nasdaq
- Market Cap
- MOLN 218.1M
- PROK 220.6M
- IPO Year
- MOLN 2021
- PROK N/A
- Fundamental
- Price
- MOLN $5.31
- PROK $1.70
- Analyst Decision
- MOLN Hold
- PROK Buy
- Analyst Count
- MOLN 1
- PROK 5
- Target Price
- MOLN $4.50
- PROK $4.50
- AVG Volume (30 Days)
- MOLN 40.7K
- PROK 437.3K
- Earning Date
- MOLN 08-26-2024
- PROK 11-12-2024
- Dividend Yield
- MOLN N/A
- PROK N/A
- EPS Growth
- MOLN N/A
- PROK N/A
- EPS
- MOLN N/A
- PROK N/A
- Revenue
- MOLN $7,105,397.00
- PROK N/A
- Revenue This Year
- MOLN N/A
- PROK N/A
- Revenue Next Year
- MOLN $29.41
- PROK N/A
- P/E Ratio
- MOLN N/A
- PROK N/A
- Revenue Growth
- MOLN N/A
- PROK N/A
- 52 Week Low
- MOLN $3.32
- PROK $1.12
- 52 Week High
- MOLN $12.70
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- MOLN 45.05
- PROK 43.50
- Support Level
- MOLN $5.67
- PROK $1.95
- Resistance Level
- MOLN $6.24
- PROK $2.27
- Average True Range (ATR)
- MOLN 0.37
- PROK 0.18
- MACD
- MOLN -0.11
- PROK 0.03
- Stochastic Oscillator
- MOLN 12.58
- PROK 26.45
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.